Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Assets (2016 - 2025)

Historic Assets for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $506.9 million.

  • Rhythm Pharmaceuticals' Assets rose 3941.5% to $506.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $506.9 million, marking a year-over-year increase of 3941.5%. This contributed to the annual value of $392.3 million for FY2024, which is 1789.0% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Assets stood at $506.9 million for Q3 2025, which was up 3941.5% from $372.7 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Assets high stood at $506.9 million for Q3 2025, and its period low was $258.7 million during Q1 2024.
  • In the last 5 years, Rhythm Pharmaceuticals' Assets had a median value of $363.6 million in 2024 and averaged $359.8 million.
  • Its Assets has fluctuated over the past 5 years, first surged by 6513.27% in 2021, then crashed by 3253.96% in 2022.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Assets stood at $329.5 million in 2021, then rose by 16.07% to $382.5 million in 2022, then dropped by 13.0% to $332.7 million in 2023, then grew by 17.89% to $392.3 million in 2024, then rose by 29.21% to $506.9 million in 2025.
  • Its Assets stands at $506.9 million for Q3 2025, versus $372.7 million for Q2 2025 and $386.7 million for Q1 2025.